Endo to pay $25M for nasal testosterone replacement therapy

Endo International made a bigger push into the testosterone replacement therapy market Monday by agreeing to acquire the rights to Natesto for $25 million. Natesto is the only testosterone nasal gel approved by the Food and Drug Administration as a replacement therapy for adult males with hypogonadism. Many testosterone gel replacement therapies are delivered through the skin in a patch or gel formulation. The condition is also treated with injectable medicines or drugs taken orally. Natesto is…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: Source Type: news